glp 1 for addiction treatment IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1s and Addiction Treatment: Setting

Neither compound has been approved as a medicine by any regulator - not the TGA in Australia, the FDA in the United States, or the EMA in Europe - for any use

Common MTHFR Genetic Mutations C677T Heterozygous +/- 30-40% reduction in MTHF production Homozygous +/+ 70-75% reduction in MTHF production A1298C Heterozygous +/- 10-20% reduction in MTHF production Homozygous +/+ 30-40% reduction in MTHF production Compound Heterozygous (C677T/A1298C) 40-60% reduction in MTHF production (Heterozygous one normal gene, one affected gene) (Homozygous one gene from mom, one gene from dad) MTHFR and MORE: METHYLATION BIOMARKERS Within the folate cycle is the gene MTHFR

Front Cell Neurosci:15

dual and triple multi-agonists in PCOS models We next scaled down the doses of the poly-agonists in both PCOS models: 50 nmol/kg of GLP1/E and 3 nmol/kg of the dual and triple agonists, as selected according to previous references 33,34,35